Eli Lilly Company News

Eli Lilly's weight-loss pill wins EU drug regulator's backing - Reuters

Eli Lilly's weight-loss pill wins EU drug regulator's backing Reuters

Eli Lilly’s Growth Is Exceptional. Is Its Valuation Asking Too Much? - Yahoo Finance

Eli Lilly’s Growth Is Exceptional. Is Its Valuation Asking Too Much? Yahoo Finance

Eli Lilly’s Retatrutide Lawsuits: What Pharmacies, Telemedicine Companies and Online Retailers Need to Know - Buchanan Ingersoll & Rooney PC

Eli Lilly’s Retatrutide Lawsuits: What Pharmacies, Telemedicine Companies and Online Retailers Need to Know Buchanan Ingersoll & Rooney PC

GLP-1s Took Eli Lilly To $1 Trillion. CEO Dave Ricks Is Betting Billions He Can Do It Again - Forbes

GLP-1s Took Eli Lilly To $1 Trillion. CEO Dave Ricks Is Betting Billions He Can Do It Again Forbes

Stock Split Watch: Is Eli Lilly Next? - The Motley Fool

Stock Split Watch: Is Eli Lilly Next? The Motley Fool

AI Stocks Lose Steam as Capital Rotates — Eli Lilly, AbbVie Near Record Highs - BigGo Finance

AI Stocks Lose Steam as Capital Rotates — Eli Lilly, AbbVie Near Record Highs BigGo Finance

Why is Eli Lilly stock rallying today? - Investing.com

Why is Eli Lilly stock rallying today? Investing.com

Why Eli Lilly Became Wall Street’s Safe Haven on a Hot CPI Day - TIKR.com

Why Eli Lilly Became Wall Street’s Safe Haven on a Hot CPI Day TIKR.com

Lilly's EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults with obesity and type 2 diabetes - Eli Lilly

Lilly's EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults with obesity and type 2 diabetes Eli Lilly

A 305,000-share sale is proposed by Eli Lilly (LLY) shareholder Lilly Endowment. - Stock Titan

A 305,000-share sale is proposed by Eli Lilly (LLY) shareholder Lilly Endowment. Stock Titan

Lilly breaks ground in Houston, one of ten U.S. manufacturing sites announced since 2020 - PR Newswire

Lilly breaks ground in Houston, one of ten U.S. manufacturing sites announced since 2020 PR Newswire

Eli Lilly stock: Wells Fargo maintains Buy rating for Eli Lilly stock at USD 1,330.00 - ad-hoc-news.de

Eli Lilly stock: Wells Fargo maintains Buy rating for Eli Lilly stock at USD 1,330.00 ad-hoc-news.de

LLY Stock Powers Higher As Obesity And Diabetes Pipeline Deepens - StocksToTrade

LLY Stock Powers Higher As Obesity And Diabetes Pipeline Deepens StocksToTrade

Eli Lilly and Company Earnings Preview: What to Expect - Yahoo Finance

Eli Lilly and Company Earnings Preview: What to Expect Yahoo Finance

Form 144 ELI LILLY AND COMPANY For: 16 October By Investing.com - Investing.com Canada

Form 144 ELI LILLY AND COMPANY For: 16 October By Investing.com Investing.com Canada

Zepbound linked to lower healthcare costs in adults over age 55 with obesity according to a real-world study - Eli Lilly

Zepbound linked to lower healthcare costs in adults over age 55 with obesity according to a real-world study Eli Lilly

Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress - Eli Lilly

Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress Eli Lilly

Eli Lilly Sues More Vendors Selling ‘Illicit’ Weight Loss Drugs - Bloomberg Law News

Eli Lilly Sues More Vendors Selling ‘Illicit’ Weight Loss Drugs Bloomberg Law News

Eli Lilly lawsuit against weight-loss drug seller gets another shave - Courthouse News

Eli Lilly lawsuit against weight-loss drug seller gets another shave Courthouse News

Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions - Eli Lilly

Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions Eli Lilly

Eli Lilly owes Nektar $90 mln in drug collaboration dispute, US jury says - Reuters

Eli Lilly owes Nektar $90 mln in drug collaboration dispute, US jury says Reuters

Eli Lilly Just Announced Game-Changing News - The Motley Fool

Eli Lilly Just Announced Game-Changing News The Motley Fool

Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market - Eli Lilly

Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market Eli Lilly

FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes - Eli Lilly

FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes Eli Lilly

Lilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause - Eli Lilly

Lilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause Eli Lilly

Lilly announces three acquisitions to build infectious disease portfolio - Eli Lilly

Lilly announces three acquisitions to build infectious disease portfolio Eli Lilly

Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes - Eli Lilly

Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes Eli Lilly

FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions - Eli Lilly

FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions Eli Lilly

Lilly to present new data on Foundayo, retatrutide, and eloraTZP at EASD 2026, as it strives to change the course of cardiometabolic health - PR Newswire

Lilly to present new data on Foundayo, retatrutide, and eloraTZP at EASD 2026, as it strives to change the course of cardiometabolic health PR Newswire

Lilly reports first-quarter 2026 financial results, raises full year guidance, and highlights momentum of new medicines - Eli Lilly

Lilly reports first-quarter 2026 financial results, raises full year guidance, and highlights momentum of new medicines Eli Lilly

Lilly commits additional $4.5 billion across Indiana manufacturing sites, opens first dedicated genetic medicine facility - Eli Lilly

Lilly commits additional $4.5 billion across Indiana manufacturing sites, opens first dedicated genetic medicine facility Eli Lilly

Eli Lilly and Company (LLY)’s Weight-Loss Pill Just Won Its First Race in Europe. Novo Nordisk A/S (NVO) Still Has a Head Start - Yahoo Finance

Eli Lilly and Company (LLY)’s Weight-Loss Pill Just Won Its First Race in Europe. Novo Nordisk A/S (NVO) Still Has a Head Start Yahoo Finance